Skip to main content
. 2013 Mar 19;54(3):665–671. doi: 10.3349/ymj.2013.54.3.665

Fig. 1.

Fig. 1

Receiving operating characteristics curves for the ERSPC-RC, the PCPT-RC, PSA, and PSAD for (A) the total patient group, (B) the group with PSA >4.0 ng/mL, (C) the group with PSAD >0.15. ERSPC-RC, European Randomized Screening of Prostate Cancer Risk Calculator; PCPT-RC, Prostate Cancer Prevention Trial Risk Calculator; PSA, prostate-specific antigen; PSAD, PSA density.